Lok Nayak Hospital is the national capital’s first COVID-19 only facility. Although Favipiravir was recently embraced in India by Glenmark Pharmaceuticals in the form of Fabiflu, this Delhi hospital has discontinued the use of the drug for COVID-19 patients. The well-known hospital has approved off label use of Ivermectin for early-stage COVID-19 patients, as well as Remdesivir, Tocilizumab, and plasma therapy.
Lok Nayak Hospital
A public hospital in the nation’s capital (Delhi), Lok Nayak Hospital, is now one of at least four providers in Delhi that only administers care to COVID-19 patients. The hospital has had some controversy in terms of reporting numbers of deaths and consequently sacked its director recently. By March, Lok Nayak Hospital had already established a 34-bed isolation ward for suspected COVID-19 patients as well as 11 isolation wards for confirmed cases. By the spring, it was one of the 27 hospitals in Delhi with COVID-19 isolation facilities.
Favipiravir In India
The oral antiviral has been approved for influenza in Japan since 2014 and is now approved for COVID-19 in Russia, China, and India. The drug is known to block a viral enzyme in RNA polymer...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).